Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analyst sentiment is mixed: Nine analysts give Keros Therapeutics a consensus “Hold” rating, split among four buys, four holds and one sell. The average 12-month price target is $20.50, versus the stock’s recent price of $11.11.
• Keros remains financially challenged: The company reported a quarterly loss of $1.45 per share, missing estimates of a $1.34 loss, and analysts expect a full-year loss of $5.27 per share.
• Institutional ownership is substantial, while insiders have recently sold: Institutions own 71.56% of KROS, with several investors adding or initiating positions, while insiders sold 5,893 shares worth about $60,507 over the past 90 days.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have received an average rating of "Hold" from the nine analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $20.50.

KROS has been the subject of a number of research analyst reports. Zacks Research raised Keros Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 27th. Leerink Partners cut their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 4th. Wall Street Zen raised shares of Keros Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Monday, August 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday, August 4th.

Insider Buying and Selling at Keros Therapeutics

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the company's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the sale, the insider directly owned 27,559 shares of the company's stock, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,893 shares of company stock worth $60,507 in the last 90 days. Insiders own 12.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KROS. California State Teachers Retirement System increased its holdings in shares of Keros Therapeutics by 72.6% during the second quarter. California State Teachers Retirement System now owns 2,729 shares of the company's stock valued at $29,000 after acquiring an additional 1,148 shares in the last quarter. Hsbc Holdings PLC boosted its stake in Keros Therapeutics by 29.5% during the 2nd quarter. Hsbc Holdings PLC now owns 69,926 shares of the company's stock valued at $761,000 after purchasing an additional 15,940 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in Keros Therapeutics during the 2nd quarter valued at $15,091,483. Empowered Funds LLC bought a new position in shares of Keros Therapeutics during the second quarter valued at $1,521,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Keros Therapeutics in the 2nd quarter worth about $538,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Trading Down 1.1%

Keros Therapeutics stock opened at $11.11 on Friday. The firm has a market cap of $220.31 million, a P/E ratio of -3.00 and a beta of 1.01. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55. The firm has a 50-day moving average of $10.80 and a 200-day moving average of $11.40.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Research analysts forecast that Keros Therapeutics will post -5.27 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source